We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Swiss drug giant Novartis is setting up a private non-profit institute in Singapore dedicated to discovering better treatments for neglected diseases that are ravaging developing countries.

The Novartis Institute for Tropical Diseases (NITD) will initially focus on multidrug-resistant tuberculosis and dengue. Any resulting drugs will be available to developing countries without royalties.

In this article, Dennis Normile describes the need for such an institute, and interviews some of the researchers who are preparing to head off to Singapore.

Reference: Science 299, 811 (2003)